Contemporary Considerations in Dyslipidemia: New Guidelines, Controversies, and Challenges
Track:
Education Sessions (CE)
Program Code: 213-L01
Date: Tuesday, December 7, 2010
Time: 8:00 AM to 11:00 AM EST
Location:
Room 304A, Level 3
PRESENTER(S):
Jennifer Clemente
Tracy Martinez, PharmD, Clinical Pharmacy Specialist, Henry Ford Health System
Currently working in ambulatory care setting, involved with lipid management, asthma management, diabetes management and medication therapy management for senior patients. Elderly patients make up a large percentage of my patient pool and have allwed me to become familiar with the particular situations facing elderly patients, especially in terms of polypharmacy.
Steven Nissen
Pamela Stamm
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Tracy Martinez, PharmD, Clinical Pharmacy Specialist, Henry Ford Health System
Currently working in ambulatory care setting, involved with lipid management, asthma management, diabetes management and medication therapy management for senior patients. Elderly patients make up a large percentage of my patient pool and have allwed me to become familiar with the particular situations facing elderly patients, especially in terms of polypharmacy.
LEARNER OUTCOMES:
Apply updated information to develop appropriate treatment strategies and therapy goals for patients.
Describe the important details of the new Adult Treatment Panel IV (ATP-IV) guidelines for the management of high cholesterol and compare/contrast with previous guidelines.
Discuss new research in cholesterol therapy, including studies looking at hemodialysis patients, venous thromboembolism (VTE) prevention, "statin" side effects, alternative treatment strategies for "statin" use, and list the pros and cons of non-statin therapies.
Identify which patients are best suited for an aggressive low-density lipoprotein (LDL) management strategy.
Review the evidence and recommendations for new treatment targets such as VLDL (very low-density lipoprotein), C-reactive protein, and percent LDL reduction.